Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Research & Development: 2012-2024

Historic Research & Development for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to $332.3 million.

  • Ascendis Pharma A's Research & Development rose 3.20% to -$78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.1 million, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $332.3 million for FY2024, which is 25.30% down from last year.
  • Ascendis Pharma A's Research & Development amounted to $332.3 million in FY2024, which was down 25.30% from $444.9 million recorded in FY2023.
  • Ascendis Pharma A's 5-year Research & Development high stood at $444.9 million for FY2023, and its period low was $297.9 million during FY2020.
  • Over the past 3 years, Ascendis Pharma A's median Research & Development value was $387.3 million (recorded in 2022), while the average stood at $388.1 million.
  • In the last 5 years, Ascendis Pharma A's Research & Development spiked by 155,559.67% in 2020 and then decreased by 25.30% in 2024.
  • Yearly analysis of 5 years shows Ascendis Pharma A's Research & Development stood at $297.9 million in 2020, then climbed by 13.62% to $338.5 million in 2021, then grew by 14.43% to $387.3 million in 2022, then increased by 14.86% to $444.9 million in 2023, then decreased by 25.30% to $332.3 million in 2024.